Clinical Trial ProgressMomentum continues to build across its two lead programs: CYB003, a deuterated psilocybin analog in Phase 3 development for major depressive disorder (MDD), and CYB004, a deuterated N,N-Dimethyltryptamine (dDMT) analog in Phase 2 for generalized anxiety disorder (GAD), with a data readout expected in mid-2025.
Financial FlexibilityThe recent announcement of a US$500 million convertible debenture facility—with US$50 million now funded—provides additional capital flexibility and extends runway beyond 2026.
Partnership ExpansionCybin has expanded its partnership with Thermo Fisher Scientific to include U.S.-based manufacturing of both CYB003 drug substance and capsules, supporting Phase 3 supply and future commercial scale-up.